MEETING MINUTES
OF THE
CENTERS FOR MEDICARE AND MEDICAID SERVICES
MEDICARE EVIDENCE DEVELOPMENT AND COVERAGE
ADVISORY COMMITTEE

July 18, 2007

Centers for Medicare and Medicaid Services
7500 Security Boulevard
Baltimore, Maryland

Medicare Evidence Development and Coverage Advisory Committee

July 18, 2007
Attendees

Alan M. Garber, M.D., Ph.D.
Chairperson
Alexander H. Krist, M.D.
Vice-Chairperson
Michelle Atkinson
Executive Secretary

Voting Members
Chaim Charytan, M.D.
A. Mark Fendrick, M.D.
Carole Redding Flamm, M.D., M.P.H.
William Lewis, M.D.
William H. Maisel, M.D., M.P.H.
Barry D. Pressman, M.D.
Sanford J. Schwartz, M.D.
Mark Slaughter, M.D.

HCFA Liaison
Steve E. Phurrough, M.D., M.P.A.
Marcel Salive, M.D.

Consumer Representative
Linda A. Bergthold, Ph.D.

Industry Representative
Michael J. Lacey, M.Sc.

Guest Expert Panelists
Matthew S. Edwards, M.D.
Stephen C. Textor, M.D.

Wednesday. July 18, 2007, 8:05 a.m.

The Medicare Evidence Development and Coverage Advisory Committee met on July 18, 2007, to discuss the evidence, hear presentations and public comment, and make recommendations regarding percutaneous transluminal angioplasty and stenting of renal arteries.
The meeting began with a reading of conflict of interest issues and an introduction of the Committee.

CMS Summary **and Presentation of Voting Questions.** A CMS representative presented the discussion and voting questions to be considered by the panel. **Presentation of the** Technology Assessment. The results of a technology assessment performed by the Tufts New England Medical Center Evidence-Based Practice Center were presented.

Other Presentations. The panel heard presentations from four additional speakers, including researchers and clinicians.

Scheduled Public Comments. Seven speakers, including professional society representatives and a manufacturers' representative addressed the panel.

Open Public Comments. Three additional representatives of professional societies addressed the panel. Following the public comments, at the request of the chair, a representative of FDA addressed the current status of FDA approval for devices used to stent renal arteries.

Questions to Presenters. The panel conducted an extensive question and answer period with the various presenters and other speakers.

Initial Open Panel Discussion. There was an extensive period of discussion surrounding the initial discussion questions, as well as the form **of the** voting questions and definitions to be applied during the deliberations and voting.

Formal **Remarks and** Voting. The panel voted on Questions 1 through 4, with the results being recorded on individual tally sheets and compiled by staff. During the voting procedure, further discussion was held among the panelists concerning each question voted upon, and individual comments were made by panelists following each vote, amplifying their reasons for voting as they did.

Final **Discussion** Questions. Following the voting, additional discussion was held by the panelists, focusing on the two final discussion questions.

Adjournment. The meeting adjourned at *2:55* p.m.

I certify that I attended the meeting
of the MedCAC Committee on
July 18, 2007, and that these minutes
accurately reflect what transpired.

Michelle L Atkinson

Michelle Atkinson
Executive Secretary, MedCAC, CMS

I approve the minutes of this meeting
as recorded in this summary.
Alan M. Garber, M.D,, Ph.D.
Chairperson